What we do
We are a science-led global healthcare company. We research and develop a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare.
We also have a significant global presence with commercial operations in more than 150 countries, a network of 84 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.
On 2 March 2015 we completed a 3-part transaction with Novartis which reshapes our business.
We acquired Novartis’s vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company. By substantially strengthening Vaccines and Consumer Healthcare, we can deliver far-reaching benefits to patients and consumers, and further value to shareholders. In addition, Novartis acquired our marketed Oncology portfolio.
More information to follow.
Our pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. In Singapore, our portfolio is made up of both patent-protected and off-patent medicines.
£15.5bn turnover, 67% of Group
Our vaccines business is one of the largest in the world, producing paediatric and adult vaccines against a range of infectious diseases. In 2014, we distributed more than 800 million doses to 170 countries, of which over 80% were supplied to developing countries. On completion of the transfer of HIB (Haemophilus Influenzae type B) production to Tuas, Singapore will be responsible for more than 20% of GSK's total vaccines production.
£3.2bn turnover, 14% of Group
We develop and market a range of consumer healthcare products based on scientific innovation. We have brands in four main categories: Wellness, Oral health, Skin health and Nutrition. In Singapore, our top brands in each category are Panadol, Sensodyne, Physiogel and Horlicks.
£4.3bn turnover, 19% of Group